Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes

Open access

Abstract

Short-chain fatty acids (SCFAs) have immunomodulatory effects, but the underlying mechanisms are not well understood. Here we show that pentanoate, a physiologically abundant SCFA, is a potent regulator of immunometabolism. Pentanoate induces IL-10 production in lymphocytes by reprogramming their metabolic activity towards elevated glucose oxidation. Mechanistically, this reprogramming is mediated by supplying additional pentanoate-originated acetyl-CoA for histone acetyltransferases, and by pentanoate-triggered enhancement of mTOR activity. In experimental mouse models of colitis and multiple sclerosis, pentanoate-induced regulatory B cells mediate protection from autoimmune pathology. Additionally, pentanoate shows a potent histone deacetylase-inhibitory activity in CD4 + T cells, thereby reducing their IL-17A production. In germ-free mice mono-colonized with segmented filamentous bacteria (SFB), pentanoate inhibits the generation of small-intestinal Th17 cells and ameliorates SFB-promoted inflammation in the central nervous system. Taken together, by enhancing IL-10 production and suppressing Th17 cells, the SCFA pentanoate might be of therapeutic relevance for inflammatory and autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-08711-2

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pentanoate inhibits induction of IL-17A. a Pathogenic Th17 cells were generated by polarizing CD4+ T cells in the presence of IL-6, IL-23, and IL-1β and increasing pentanoate concentrations. Staining for IL-17A and CFSE is shown as a representative of three similar experiments. b RNA-seq analysis of pathogenic Th17 cells in the presence or absence of pentanoate. Heatmap of downregulated Th17-associated genes is shown. The FPKM values were z-transformed and plotted. c Clinical EAE scores for WT, GF, GF + SFB and GF + SFB mice treated with pentanoate as described in Methods. Mice were immunized with MOG peptide emulsified in CFA + pertussis toxin (n = 6 animals per group from one representative experiment of two). Mice were monitored daily for the progression of EAE. d Representative contour plots showing the frequency of IFN-γ+ and IL-17A+CD4+ in the central nervous system (CNS) and small intestine (SI) among different mice groups on day 18 after EAE induction. e Absolute cell numbers of IL-17A+ and IL-17A+IFN-γ+CD4+ T cells in four group of mice treated as described in (c) and analyzed on day 18 after EAE induction. f Percentages of IL-17A+ (CNS and SI) and IL-17A+IFN-γ+CD4+ T cells (CNS) in WT, GF, GF + SFB mice, and GF + SFB animals treated with pentanoate on day 18 after EAE induction. Error bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA test)
Fig. 1 Pentanoate inhibits induction of IL-17A. a Pathogenic Th17 cells were generated by polarizing CD4+ T cells in the presence of IL-6, IL-23, and IL-1β and increasing pentanoate concentrations. Staining for IL-17A and CFSE is shown as a representative of three similar experiments. b RNA-seq analysis of pathogenic Th17 cells in the presence or absence of pentanoate. Heatmap of downregulated Th17-associated genes is shown. The FPKM values were z-transformed and plotted. c Clinical EAE scores for WT, GF, GF + SFB and GF + SFB mice treated with pentanoate as described in Methods. Mice were immunized with MOG peptide emulsified in CFA + pertussis toxin (n = 6 animals per group from one representative experiment of two). Mice were monitored daily for the progression of EAE. d Representative contour plots showing the frequency of IFN-γ+ and IL-17A+CD4+ in the central nervous system (CNS) and small intestine (SI) among different mice groups on day 18 after EAE induction. e Absolute cell numbers of IL-17A+ and IL-17A+IFN-γ+CD4+ T cells in four group of mice treated as described in (c) and analyzed on day 18 after EAE induction. f Percentages of IL-17A+ (CNS and SI) and IL-17A+IFN-γ+CD4+ T cells (CNS) in WT, GF, GF + SFB mice, and GF + SFB animals treated with pentanoate on day 18 after EAE induction. Error bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA test)CC BY · PubMed Central
Fig. 2 Pentanoate induces IL-10 expression in Th17 cells. a Bar graphs show the HDAC activity in whole cell lysates obtained from murine CD4+ T cells treated with SCFAs (5 mM) or TSA (500 nM). The HDAC activity of untreated CD4+ T cells is arbitrary set to 1 (n = 3). b–d CD4+ T cells isolated from FIR x tiger mice were polarized under Th17-inducing conditions and treated with TSA (10 nM), pentanoate (5 mM) or pentanoate + 2-DG (2 mM). Cells were analyzed by flow cytometry (b) and fluorescence microscopy (c, d, scale bar = 25 micron) for CD4 (blue), IL-17A (red) and GFP (green) expression on day 4 of the cell culture. For counting of cytokine-positive cells, the CTCF method was used as described in Methods. ***P < 0.001 (Student's t-test). e CD4+ T cells isolated from spleens and LNs were polarized under Th17- or Treg-inducing conditions for 3 days. A representative ECAR measurement of Th17 cells polarized in the presence and absence of pentanoate is shown (Tregs served as control cells). Three independent experiments were performed. f Detection of the main components of the AKT/mTOR signaling pathway by immunoblotting of Th17 cell lysates after treatment with pentanoate. Three similar experiments were performed
Fig. 2 Pentanoate induces IL-10 expression in Th17 cells. a Bar graphs show the HDAC activity in whole cell lysates obtained from murine CD4+ T cells treated with SCFAs (5 mM) or TSA (500 nM). The HDAC activity of untreated CD4+ T cells is arbitrary set to 1 (n = 3). b–d CD4+ T cells isolated from FIR x tiger mice were polarized under Th17-inducing conditions and treated with TSA (10 nM), pentanoate (5 mM) or pentanoate + 2-DG (2 mM). Cells were analyzed by flow cytometry (b) and fluorescence microscopy (c, d, scale bar = 25 micron) for CD4 (blue), IL-17A (red) and GFP (green) expression on day 4 of the cell culture. For counting of cytokine-positive cells, the CTCF method was used as described in Methods. ***P < 0.001 (Student's t-test). e CD4+ T cells isolated from spleens and LNs were polarized under Th17- or Treg-inducing conditions for 3 days. A representative ECAR measurement of Th17 cells polarized in the presence and absence of pentanoate is shown (Tregs served as control cells). Three independent experiments were performed. f Detection of the main components of the AKT/mTOR signaling pathway by immunoblotting of Th17 cell lysates after treatment with pentanoate. Three similar experiments were performedCC BY · PubMed Central
Fig. 3 Pentanoate-mediated glucose oxidation is linked to induction of IL-10 expression. a, b Th17 cells purified and generated from the spleens and LNs of FIR x tiger mice were treated with AMPK activator (metformin) or AKT (AKT inhibitor IV) and mTOR (rapamycin) inhibitors in the presence of pentanoate. The frequency of IL-10+ and IL-17A+ cells within Th17 lymphocytes was analyzed by flow cytometry (a). The secretion of IL-10 was determined by ELISA (b). Three experiments were performed. c ATP production by Th17 cells in the absence or presence of pentanoate (2.5 mM). Three experiments were performed. d, e Th17 cells were treated with 2.5 mM pentanoate in the presence of increasing concentrations of glucose (d) or L-Glutamine (e). Three experiments were performed. f Cellular acetyl-CoA concentrations in pentanoate-treated Th17 cells were measured using fluorometric acetyl-CoA assay kit. g IL-10 secretion by pentanoate-treated Th17 cells in the presence of PKM2 (shikonin) or ACLY (SB204990) inhibitors was measured by ELISA (n = 3). h Th17 cells were treated with DCA in the presence or absence of 2-DG for 3 days. IL-10 secretion was determined by ELISA (n = 3). i ChIP analysis of acetylated H4 at the Il10 promoter in pentanoate-treated Th17 cells. Three similar experiments were performed. j IL-10 secretion by Th17 cells cultured for 3 days upon TSA or acetate treatment. Pentanoate-treated Th17 cells served as a positive control for ELISA measurement. Acetate-treated cells were additionally treated with 2-DG (1 mM). Error bars indicate SEM. n.s. = not significant, *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test)
Fig. 3 Pentanoate-mediated glucose oxidation is linked to induction of IL-10 expression. a, b Th17 cells purified and generated from the spleens and LNs of FIR x tiger mice were treated with AMPK activator (metformin) or AKT (AKT inhibitor IV) and mTOR (rapamycin) inhibitors in the presence of pentanoate. The frequency of IL-10+ and IL-17A+ cells within Th17 lymphocytes was analyzed by flow cytometry (a). The secretion of IL-10 was determined by ELISA (b). Three experiments were performed. c ATP production by Th17 cells in the absence or presence of pentanoate (2.5 mM). Three experiments were performed. d, e Th17 cells were treated with 2.5 mM pentanoate in the presence of increasing concentrations of glucose (d) or L-Glutamine (e). Three experiments were performed. f Cellular acetyl-CoA concentrations in pentanoate-treated Th17 cells were measured using fluorometric acetyl-CoA assay kit. g IL-10 secretion by pentanoate-treated Th17 cells in the presence of PKM2 (shikonin) or ACLY (SB204990) inhibitors was measured by ELISA (n = 3). h Th17 cells were treated with DCA in the presence or absence of 2-DG for 3 days. IL-10 secretion was determined by ELISA (n = 3). i ChIP analysis of acetylated H4 at the Il10 promoter in pentanoate-treated Th17 cells. Three similar experiments were performed. j IL-10 secretion by Th17 cells cultured for 3 days upon TSA or acetate treatment. Pentanoate-treated Th17 cells served as a positive control for ELISA measurement. Acetate-treated cells were additionally treated with 2-DG (1 mM). Error bars indicate SEM. n.s. = not significant, *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test)CC BY · PubMed Central
Fig. 4 Pentanoate enhances IL-10 expression in Bregs. a Splenic B cells purified from spleens of FIR × tiger mice were activated with CpG in the absence or presence of pentanoate. Representative dot plots show the frequencies of IL-10+ B cells on day 4 of the cell culture. b Representative RT-qPCR analysis of Il10 expression in Bregs treated with pentanoate for 3 days (one of three similar experiment is shown). c Bar graphs indicate secreted amounts of IL-10 by Bregs incubated for 3 days with various SCFAs or with TSA. Three experiments were performed. d, e B cells were treated as described in (a) and analyzed via RNA-seq. PCA (d) was performed on FPKM values. Heatmap (e) of cell death- and survival-associated genes, regulated upon pentanoate treatment, and overlapping with gene sets based on the IPA-database are shown. FPKM values of overlapping genes were z-transformed and plotted. f Histogram (left) and bar graphs (right) showing the frequency of Annexin V+ Bregs treated with SCFAs pentanoate (5 mM) or butyrate (5 mM) for 24 h. Three independent experiments were performed. Error bars indicate SEM. n.s. = not significant, **P < 0.01, ***P < 0.001 (Student's t-test)
Fig. 4 Pentanoate enhances IL-10 expression in Bregs. a Splenic B cells purified from spleens of FIR × tiger mice were activated with CpG in the absence or presence of pentanoate. Representative dot plots show the frequencies of IL-10+ B cells on day 4 of the cell culture. b Representative RT-qPCR analysis of Il10 expression in Bregs treated with pentanoate for 3 days (one of three similar experiment is shown). c Bar graphs indicate secreted amounts of IL-10 by Bregs incubated for 3 days with various SCFAs or with TSA. Three experiments were performed. d, e B cells were treated as described in (a) and analyzed via RNA-seq. PCA (d) was performed on FPKM values. Heatmap (e) of cell death- and survival-associated genes, regulated upon pentanoate treatment, and overlapping with gene sets based on the IPA-database are shown. FPKM values of overlapping genes were z-transformed and plotted. f Histogram (left) and bar graphs (right) showing the frequency of Annexin V+ Bregs treated with SCFAs pentanoate (5 mM) or butyrate (5 mM) for 24 h. Three independent experiments were performed. Error bars indicate SEM. n.s. = not significant, **P < 0.01, ***P < 0.001 (Student's t-test)CC BY · PubMed Central
Fig. 5 Pentanoate-induced IL-10 expression in Bregs is dependent on glycolysis and p38 MAPK activity. a Bregs were generated with 4 μg/ml CpG and 5 mM pentanoate in presence of increasing amounts of p38 inhibitor SB203580. IL-10 secretion was determined by ELISA. Three experiments were performed. b ECAR measurement of CpG-induced Bregs generated in the presence and absence of pentanoate. Three independent experiments were performed. c Bar graphs show Hk2 expression in pentanoate-treated Bregs on day 3 of the cell culture. One of three similar experiments is shown. d Immunoblot analysis of main components of AKT/mTOR signaling pathway in murine Bregs in the presence of pentanoate (5 mM). Three similar experiments were performed. e, f ELISA (e) and FACS analysis (f) of CD19+IL-10+ Bregs generated with CpG and pentanoate in the presence of AMPK activator (metformin) or PI3K (wortmannin), PDK1 (GSK2334470), mTOR (rapamycin), and AKT (AKT inhibitor IV) inhibitors with or without SB203580. Three experiments were carried out. Error bars indicate SEM. ***P < 0.001 (Student's t-test)
Fig. 5 Pentanoate-induced IL-10 expression in Bregs is dependent on glycolysis and p38 MAPK activity. a Bregs were generated with 4 μg/ml CpG and 5 mM pentanoate in presence of increasing amounts of p38 inhibitor SB203580. IL-10 secretion was determined by ELISA. Three experiments were performed. b ECAR measurement of CpG-induced Bregs generated in the presence and absence of pentanoate. Three independent experiments were performed. c Bar graphs show Hk2 expression in pentanoate-treated Bregs on day 3 of the cell culture. One of three similar experiments is shown. d Immunoblot analysis of main components of AKT/mTOR signaling pathway in murine Bregs in the presence of pentanoate (5 mM). Three similar experiments were performed. e, f ELISA (e) and FACS analysis (f) of CD19+IL-10+ Bregs generated with CpG and pentanoate in the presence of AMPK activator (metformin) or PI3K (wortmannin), PDK1 (GSK2334470), mTOR (rapamycin), and AKT (AKT inhibitor IV) inhibitors with or without SB203580. Three experiments were carried out. Error bars indicate SEM. ***P < 0.001 (Student's t-test)CC BY · PubMed Central
Fig. 6 Pentanoate-treated Bregs protect mice from EAE development. a–g EAE development in mice in the presence or absence of pentanoate-induced Bregs. For induction of EAE, FIR × tiger mice were immunized with MOG peptide. A control group of Bregs (BregsCpG) was treated with vehicle (water). Pentanoate-treated Bregs (BregsPent) were generated in the absence or presence of rapamycin (100 nM) and SB203580 (5 μM). Mice received 2 × 106 sorted GFP+ Bregs on day 0 and day 8 (a–c and e–g) or only on day 8 (d) post immunization (n = 6 mice per group from one representative experiment of two). Mice were monitored daily for EAE progression. Total cell number of pathogenic CD4+ T lymphocytes in the CNS on day 17(a, d) or day 15 (e) after EAE development was analyzed by flow cytometry. Black arrows indicate the day of administration of Bregs (a, d). Error bars indicate SEM, n.s. = not significant; *P < 0.05; **P < 0.01, ***P < 0.001 (one-way ANOVA test)
Fig. 6 Pentanoate-treated Bregs protect mice from EAE development. a–g EAE development in mice in the presence or absence of pentanoate-induced Bregs. For induction of EAE, FIR × tiger mice were immunized with MOG peptide. A control group of Bregs (BregsCpG) was treated with vehicle (water). Pentanoate-treated Bregs (BregsPent) were generated in the absence or presence of rapamycin (100 nM) and SB203580 (5 μM). Mice received 2 × 106 sorted GFP+ Bregs on day 0 and day 8 (a–c and e–g) or only on day 8 (d) post immunization (n = 6 mice per group from one representative experiment of two). Mice were monitored daily for EAE progression. Total cell number of pathogenic CD4+ T lymphocytes in the CNS on day 17(a, d) or day 15 (e) after EAE development was analyzed by flow cytometry. Black arrows indicate the day of administration of Bregs (a, d). Error bars indicate SEM, n.s. = not significant; *P < 0.05; **P < 0.01, ***P < 0.001 (one-way ANOVA test)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 525

Metadata

Authors
Luu, M., Pautz, S., Kohl, V., Singh, R., Romero, R., Lucas, S., Hofmann, J., Raifer, H., Vachharajani, N., Carrascosa, L. C., Lamp, B., Nist, A., Stiewe, T., Shaul, Y., Adhikary, T., Zaiss, M. M., Lauth, M., Steinhoff, U., & Visekruna, A.
Affiliations
  • Philipps University of Marburg (DE)
  • University of Kassel (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Hebrew University of Jerusalem (IL)
Corresponding author
Visekruna, Alexander
Venue
Nature Communications
Published
2019-02-15
Volume
10
Issue
1
Pages
760-760
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2911672024
Cited by
508
References
51
Citations by year
2026: 51 · 2025: 92 · 2024: 95 · 2023: 75 · 2022: 86 · 2021: 50 · 2020: 44 · 2019: 14
FWCI
16.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Philipps-Universität Marburg
  • Helmholtz Zentrum München
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
short-chain fatty acids, immunometabolism, autoimmunity, IL-10, glucose oxidation, acetyl-CoA, histone acetylation, histone deacetylase inhibition, mTOR, regulatory B cells, Th17 cells, segmented filamentous bacteria, colitis, multiple sclerosis, CD4+ T cells, IL-17A, germ-free mice
MeSH terms
Animals, Colitis, Fatty Acids, Volatile, Lymphocytes, Multiple Sclerosis, Valerates, CD4-Positive T-Lymphocytes, Autoimmunity, Interleukin-10, Epigenesis, Genetic, Mice, Th17 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. https://app.cochat.ai/papers/10.1038/s41467-019-08711-2
The paper
Luu, M., Pautz, S., Kohl, V., Singh, R., Romero, R., Lucas, S., Hofmann, J., Raifer, H., Vachharajani, N., Carrascosa, L. C., Lamp, B., Nist, A., Stiewe, T., Shaul, Y., Adhikary, T., Zaiss, M. M., Lauth, M., Steinhoff, U., & Visekruna, A. (2019). The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nature Communications. https://doi.org/10.1038/s41467-019-08711-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.